| WHO - Prequalification of Medical Products (IVDs, Medicines, Vaccines and Immunization Devices, Vector Control)

WHO Public Assessment Reports (WHOPARs) published

Announcement

6 February, 2025 - 13:41 (CET)

Active Pharmaceutical Ingredient (API) Prequalified

Announcement

29 January, 2025 - 00:12 (CET)

Albendazole (WHOAPI-427) manufactured by Sequent Scientific Limited has been prequalified by the WHO Prequalification Team medicines under its API prequalification procedure.

WHO Public Assessment Reports (WHOPARs) published

Announcement

24 January, 2025 - 15:59 (CET)

WHO Public Assessment Reports (WHOPARs) published

Announcement

24 January, 2025 - 15:49 (CET)

RFP: Post Market Monitoring Country Technical Support: Cold Chain Information System (CCIS) data collection tool completion, learning materials and ‘help-desk’

Announcement

23 January - 11 February, 2025 - 12:06 - 23:59 (CET)

WHO prequalifies diagnostic test to support safer administration of P. vivax malaria treatments

IVD

Announcement

16 January, 2025 - 14:42 (CET)

WHO Public Assessment Reports (WHOPARs) published

Announcement

13 January, 2025 - 10:31 (CET)

Biopharmaceutics Classification System (BCS)-based Biowaivers

6 January, 2025 - 00:12 (CET)

Effective January 1, 2025, PQT/MED will implement the use of the

Medopharm’s chewable albendazole tabl prequalified

25 December, 2024 - 12:12 (CET)

WHO Prequalification Unit (PQT) added the below new product to its prequalified list:

NT012 Albendazole Tablets, Chewable 400mg – Medopharm - INDIA

Active Pharmaceutical Ingredient (API) Prequalified

Announcement

19 December, 2024 - 12:12 (CET)

Dihydroartemisinin manufactured by Guilin Pharmaceutical Co., Ltd.

Subscribe to